Loss of Stag2 cooperates with EWS-FLI1 to transform murine Mesenchymal stem cells

Marc El Beaino1, Jiayong Liu2, Amanda R Wasylishen3

  • 1Department of Orthopaedic Oncology - Unit 1448, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.

BMC Cancer
|January 4, 2020
PubMed
Abstract

Insights

Loss of Stag2 cooperates with EWS-FLI1 to promote sarcoma development in murine mesenchymal stem cells (MSCs). This suggests Stag2 is a key factor in EWS-FLI1-driven sarcomas, though other genetic changes are likely involved.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Ewing sarcoma is a primitive cell malignancy, likely of mesenchymal origin.
  • Genetic alterations beyond EWS-FLI1 are implicated in tumor development.
  • STAG2 mutations are found in approximately 15% of human Ewing sarcoma cases.

Purpose of the Study:

  • To investigate the hypothesis that loss of Stag2 cooperates with EWS-FLI1 in generating sarcomas.
  • To study sarcoma development in murine mesenchymal stem cells (MSCs).

Main Methods:

  • Mice with inducible EWS-FLI1 and p53 knockout were used.
  • Murine MSCs were isolated and treated with EWS-FLI1 induction and Stag2 knockdown via lentiviral infection.
  • Cells were irradiated, and tumor formation, migration, invasion, proliferation, and aneuploidy were assessed.

Main Results:

  • Stag2 inhibition significantly increased sarcoma formation efficiency and speed in irradiated EWS-FLI1 p53-/- MSCs (91% vs. 22%).
  • Stag2 knockdown reduced mouse survival and enhanced MSC migration and invasion in vitro.
  • Proliferation rate and aneuploidy were not affected by Stag2 knockdown.

Conclusions:

  • Loss of Stag2 synergizes with EWS-FLI1 in sarcoma production from murine MSCs.
  • The mechanism does not appear to involve increased proliferation or chromosomal instability.
  • Irradiation is essential in this model, indicating other genetic perturbations are likely necessary for EWS-FLI1-driven sarcoma development.